Literature DB >> 1116107

The efficacy of combining radiation therapy with a surgical procedure in patients with cervical metastasis from squamous cancer of the oropharynx and hypopharynx.

R H Jesse, R D Lindberg.   

Abstract

To determine whether combining radiation therapy and a surgical procedure was superior to either modality alone, the authors reviewed the records of 345 patients who had primary cancers of the base of the tongue, tonsillar fossa, or pyriform sinus associated with clinically positive nodes at the time of their first observation. Combining the two modalities of therapy produced a local and regional control of the disease in twice as many patients as did one modality alone. The absolute 5-year survival did not reflect this same trend, however, since as local and regional control increased, more patients lived longer but died before five years from distant metastases. Immunochemotherapy is suggested as a possible adjunct therapy to prevent distant metastases.

Entities:  

Mesh:

Year:  1975        PMID: 1116107     DOI: 10.1002/1097-0142(197504)35:4<1163::aid-cncr2820350422>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

Authors:  A Chahlavi; T Todo; R L Martuza; S D Rabkin
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 2.  Transoral robotic surgery and a paradigm shift in the management of oropharyngeal squamous cell carcinoma.

Authors:  Harry Quon; Bert W O'Malley; Gregory S Weinstein
Journal:  J Robot Surg       Date:  2010-06-29

Review 3.  [Combined modality approaches in the treatment of head and neck cancer patients].

Authors:  C Simon; P K Plinkert
Journal:  HNO       Date:  2008-06       Impact factor: 1.284

Review 4.  Ion Transport and Radioresistance.

Authors:  Bastian Roth; Stephan M Huber
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.